Tirzepatide Injectable Vials Recalled for Sterility Assurance
ProRx LLC is recalling Tirzepatide 20 mg/2mL injectable vials nationwide due to lack of assurance of sterility. Patients who received vials from lot ProRx051424 should contact their healthcare provider.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall for a risk-of-harm injectable product where no injury has been reported. Lack of sterility assurance in an injectable medication poses potential infection risk, but no illnesses or injuries are documented.
Plain-English summary
ProRx LLC is recalling Tirzepatide 20 mg/2mL injectable vials distributed nationwide. The affected product is a 2mL multiple-dose vial with lot number ProRx051424, bearing a beyond-use date of 11/13/2024. Approximately 1,489 vials are affected by this recall.
The recall was initiated due to lack of assurance of sterility. Tirzepatide is an injectable medication used in diabetes and weight management treatment. Loss of sterility assurance in an injectable product poses a potential infection risk if the product is used.
Patients who have received or may receive vials from this lot should contact their healthcare provider or pharmacist immediately. Do not use the product if you have a vial from the affected lot.
The recalled product
- Product
- TIRZEPATIDE 20 mg/2mL (10/mg/mL), Rx Only, 2mL Multiple Dose Vial, Mfd by: ProRx Exton, PA, 19341, NDC 84139-210-01
- Manufacturer
- ProRx LLC
- Category
- Drug — Injectable
- Hazard
- sterility-risk
- infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # ProRx051424
- BUD 11/13/2024
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- ModerateGas-X Simethicone 125 mg softgels recall for incomplete labeling
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27